Crispr Therapeutics shares tumble after significant earnings miss
McKesson Corporation (NYSE:MCK) stock has reached an unprecedented peak, setting an all-time high at $637.59. According to InvestingPro analysis, the company maintains a "GOOD" overall financial health score, with particularly strong momentum metrics, suggesting potential for further growth. This milestone underscores the company’s robust performance in the healthcare sector, reflecting investor confidence and market momentum. Over the past year, McKesson has seen a significant uptick in its stock value, with a 1-year total return of 19.11%. The company’s strong position is further evidenced by its $79.7 billion market capitalization and impressive 14.3% revenue growth. InvestingPro subscribers can access 14 additional key insights about MCK’s performance and outlook. This growth trajectory highlights the company’s strategic initiatives and its strong position within the industry, as it continues to adapt and thrive in a dynamic healthcare landscape. With a stable beta of 0.52 indicating lower volatility than the broader market, and a 32-year track record of consistent dividend payments, McKesson demonstrates remarkable stability in an evolving sector.
In other recent news, McKesson Corporation reported third-quarter earnings that fell short of analyst expectations, with adjusted earnings per share at $8.03 compared to the anticipated $8.27. Revenue for the quarter reached $95.29 billion, marking an 18% year-over-year increase, though still below the forecasted $95.77 billion. Despite the earnings miss, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55-$32.95, slightly above the analyst consensus midpoint of $32.67. The U.S. Pharmaceutical (TADAWUL:2070) segment saw a 19% revenue increase, driven by higher prescription volumes and oncology platform growth.
Additionally, McKesson announced plans to acquire a controlling interest in PRISM Vision Holdings LLC for $850 million and Florida Cancer Specialists & Research Institute for $2.5 billion. These acquisitions are part of McKesson’s strategy to expand its specialty services. S&P Global Ratings revised its outlook on McKesson to positive, affirming a ’BBB+’ rating, citing expected growth in the U.S. pharmaceutical segment and prescription technology business. Citi analyst Daniel Grosslight raised the price target for McKesson shares to $685, maintaining a Buy rating, following the company’s mixed financial performance. McKesson’s U.S. Pharma segment exceeded expectations with a 14% year-over-year growth in adjusted operating profit, despite some underperformance in the Med-Surg division.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.